The partners aim to identify microRNAs that can be used to identify patients likely to respond to PD-L1-targeting cancer drugs.
Using small RNA sequencing, investigators found miRNAs in the blood that track with cirrhosis, hepatitis, type 2 diabetes, or acetaminophen toxicity.
The partners have formed a public/private partnership to foster collaboration and data integration between different institutes researching brain trauma.
The grant will fund a collaboration investigating whether genomic signatures and other biomarkers can be used in clinical diagnosis and monitoring of kidney cancer.
The collaborators are each providing funding and samples, and plan to study about 100 patients with a subset of Castleman disease to identify biomarkers.
Cancer Genetics will help analyze biomarkers to identify response patient populations, as well as reflect the mechanism of action of Effector's eFT508.
Poly(GP) proteins could be detected within ALS patients samples and used to determine whether ALS drugs under development are reaching their targets.
Researchers hope to identify exosomal biomarkers that can predict or detect cancer recurrence and metastasis at its earliest stages.
The companies have expanded their relationship to include the development and automation of assays for clinical trials and clinical testing.
New data from Peregrine Pharmaceuticals, along with other recent research, suggests that surface proteins can be used to isolate cancer-specific exosomes to detect the presence of a tumor.
The companies will work together to create an end-to-end workflow for biomarker and drug target validation, and assay development.
The companies will work together to identify novel biomarkers of the rare genetic disorder Angelman syndrome.
The study seeks to identify biomarkers that can help personalize treatment for patients by identifying signs of rapid decline in kidney function.
The project aims to elucidate markers of response and non-response to current treatment regimens, and to identify new therapies.
The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
Bio-Techne will provide a bioanalytical assay for the group to assess and validate as a bioanalytical method for clinical trial recruitment.
The Genomics Evidence Neoplasia Information Exchange aims to provide insights through the analysis of data from tens if not hundreds of thousands of patient results.
BMS has provided funding to the diagnostic company to support build-out of its new lab and development of its platform, which they hope can identify new biomarkers for Opdivo.
The study, which is still ongoing, also provided support for a separate Phase 2/3 trial of a targeted treatment for the neurodevelopmental disorder.
CGI will provide target identification and biomarker discovery services for three cancer drugs that BeiGene is currently developing.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.